ERBB2 and breast cancer: The GIPC1 signature is also strongly associated patient survival within the ERBB2+/ER+ (n = 42, P<0.001), luminal B (n = 146, P<0.05) and basal (n = 92, P<0.01) molecular breast cancer subtypes (Table 3).